Common Contracts

EX-10.1 2 d666131dex101.htm EX-10.1 [***] Text omitted and filed separately with the Securities and Exchange Commission/Confidential Treatment Requested under 17 C.F.R. Section 240.24b-2

Development, License and Commercialization Agreement • May 5th, 2020 • New York

• Contract Type
  Development, License and Commercialization Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and effective as of December 18, 2018 (the “Effective Date”) by and between Endo Ventures Limited, an Irish company, with offices located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation, with offices located at 355 Alhambra Circle Suite 1250, Coral Gables, FL, USA (“Catalyst”).

Text omitted and filed separately with the Securities and Exchange Commission/Confidential Treatment Requested under 17 C.F.R. Section 240.24b-2

Development, License and Commercialization Agreement • December 26th, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Development, License and Commercialization Agreement
• Filed
  December 26th, 2018
• Company
  Catalyst Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and effective as of December 18, 2018 (the “Effective Date”) by and between Endo Ventures Limited, an Irish company, with offices located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation, with offices located at 355 Alhambra Circle Suite 1250, Coral Gables, FL, USA (“Catalyst”).